The Real Breakthrough Is Not a Drug, But the Platform Race

The latest science cycle is defined less by isolated discoveries than by systems that can be scaled, reused and commercialized. Oral GLP-1 therapy is the near-term prize, but the deeper shift is toward platform technologies that compress the distance between lab novelty and industrial value.